Investigating the relationship between cell cycle stage and diosgenin-induced megakaryocytic differentiation of HEL cells using sedimentation field-flow fractionation.
Differentiation therapy could be one strategy for stopping cancer cell proliferation. A plant steroid, diosgenin, is known to induce megakaryocytic differentiation in human erythroleukemia (HEL) cells. In recent studies, the use of sedimentation field-flow fractionation (SdFFF) allowed the preparation of subpopulations that may differ in regard to sensitivity to differentiation induction. The specific goal of this study was to determine the relationship between cell cycle stage and sensitivity to megakaryocytic differentiation induction of HEL cells. After first confirming the capacity of diosgenin to specifically select targets, hyperlayer SdFFF cell sorting was used to prepare fractions according to cell cycle position from crude HEL cells. The sensitivities of these fractions to diosgenin-induced differentiation were then tested. The coupling of SdFFF cell separation to imaging flow cytometry showed that G1-phase cells were more sensitive to differentiation induction than S/G2M-phase cells, confirming the relationship between cell status at the start of induction, the extent of the biological event, and the potential of SdFFF in cancer research.
Cailleteau
Clementine
C
Institut GEIST, EA 4021, Biomolécules et thérapies anti-tumorales, Faculté de Pharmacie, Laboratoire de Biochimie, Université de Limoges, 87025, Limoges Cedex, France.
Micallef
Ludovic
L
Lepage
Clemence
C
Cardot
Philippe Jean-Paul
PJ
Beneytout
Jean-Louis
JL
Liagre
Bertrand
B
Battu
Serge
S
D002453:Cell Cycle / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects*; D045744:Cell Line, Tumor; D004144:Diosgenin / Q000494:pharmacology*; D031521:Fractionation, Field Flow / Q000379:methods*; D006801:Humans; D008533:Megakaryocytes / Q000187:drug effects*; D013056:Spectrophotometry, Ultraviolet
D004144:Diosgenin